DK1165613T3 - Melanocortinreceptorligander - Google Patents

Melanocortinreceptorligander

Info

Publication number
DK1165613T3
DK1165613T3 DK00919500T DK00919500T DK1165613T3 DK 1165613 T3 DK1165613 T3 DK 1165613T3 DK 00919500 T DK00919500 T DK 00919500T DK 00919500 T DK00919500 T DK 00919500T DK 1165613 T3 DK1165613 T3 DK 1165613T3
Authority
DK
Denmark
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Application number
DK00919500T
Other languages
Danish (da)
English (en)
Inventor
Russell James Sheldon
Adam Wieslaw Mazur
Feng Wang
Frank Hal Ebetino
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of DK1165613T3 publication Critical patent/DK1165613T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
DK00919500T 1999-03-29 2000-03-21 Melanocortinreceptorligander DK1165613T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29
PCT/US2000/007473 WO2000058361A1 (fr) 1999-03-29 2000-03-21 Ligands du recepteur de melanocortine

Publications (1)

Publication Number Publication Date
DK1165613T3 true DK1165613T3 (da) 2008-08-25

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00919500T DK1165613T3 (da) 1999-03-29 2000-03-21 Melanocortinreceptorligander

Country Status (34)

Country Link
US (2) US6613874B1 (fr)
EP (1) EP1165613B1 (fr)
JP (1) JP2002542159A (fr)
KR (2) KR100558131B1 (fr)
CN (1) CN1249086C (fr)
AR (1) AR023201A1 (fr)
AT (1) ATE393783T1 (fr)
AU (1) AU763510B2 (fr)
BR (1) BR0009497A (fr)
CA (1) CA2368431C (fr)
CO (1) CO5170531A1 (fr)
CZ (1) CZ20013407A3 (fr)
DE (1) DE60038734T2 (fr)
DK (1) DK1165613T3 (fr)
ES (1) ES2304345T3 (fr)
HK (1) HK1044954B (fr)
HU (1) HUP0202203A3 (fr)
ID (1) ID30262A (fr)
IL (1) IL145406A0 (fr)
MA (1) MA25403A1 (fr)
MX (1) MXPA01009881A (fr)
MY (1) MY126585A (fr)
NO (1) NO20014568L (fr)
NZ (1) NZ514141A (fr)
PE (1) PE20001641A1 (fr)
PL (1) PL350095A1 (fr)
PT (1) PT1165613E (fr)
RU (1) RU2213098C2 (fr)
SA (1) SA00210192B1 (fr)
SK (1) SK13082001A3 (fr)
TR (1) TR200102765T2 (fr)
TW (1) TWI250990B (fr)
WO (1) WO2000058361A1 (fr)
ZA (1) ZA200107411B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (fr) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Metallopeptides de melanocortine pour le traitement de dysfonctions sexuelles
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6693165B2 (en) 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
PL366630A1 (en) 2000-08-30 2005-02-07 F.Hoffmann-La Roche Ag Selective cyclic peptides
CN1571796A (zh) * 2000-09-27 2005-01-26 宝洁公司 黑皮素受体配体
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP2006527772A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
MXPA05013951A (es) * 2003-06-19 2006-02-24 Lilly Co Eli Agonsita del receptor de la melanocortina 4 (mc4) y sus usos.
EP1670815A2 (fr) * 2003-09-30 2006-06-21 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP2332968B1 (fr) * 2003-11-05 2016-05-04 Dana-Farber Cancer Institute, Inc. Peptides alpha-hélicaux pour l'activation ou l'inhibition de la mort cellulaire
CA2552043A1 (fr) 2004-01-21 2005-08-04 Novo Nordisk A/S Conjugaison de peptides induite par la transglutaminase
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
CA2557739A1 (fr) * 2004-03-29 2005-11-03 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
WO2006041769A2 (fr) * 2004-10-05 2006-04-20 Merck & Co., Inc. Procedes de traitement d'un abus d'une substance d'une addiction a cette substance
WO2006060873A1 (fr) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Procede de restauration de la fonction reproductrice
WO2006073771A2 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
WO2006073772A1 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides agonistes de mc4r ou de mc3r lies a un polyethyleneglycol
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
KR101232201B1 (ko) 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
EP1968995A1 (fr) * 2005-12-30 2008-09-17 F. Hoffmann-la Roche AG Procede de synthese de peptides contenant arginine
EP2035373B1 (fr) 2006-06-09 2011-05-04 Action Pharma A/S Dérivés de phényl pyrrole aminoguanidine
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (fr) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Systemes de macrocyclisation bis-sulfhydryle
EP2118123B1 (fr) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
EP3301108A1 (fr) 2007-02-23 2018-04-04 Aileron Therapeutics, Inc. Systèmes macrocycliques de triazole
WO2008121767A2 (fr) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Polypeptides cousus
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
KR20100126361A (ko) 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
US20090326192A1 (en) * 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
AU2009257631B2 (en) 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
WO2010011313A2 (fr) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligature de polypeptides agrafés
CA2737921C (fr) 2008-09-22 2019-01-15 Aileron Therapeutics, Inc. Methodes de preparation de compositions de macrocycles peptidomimetiques alpha-helicoidaux purifies ayant des taux faibles de ppm de metal
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
MX2011013117A (es) 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
US9163330B2 (en) 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2480565A4 (fr) 2009-09-22 2014-01-01 Aileron Therapeutics Inc Macrocycles peptidomimétiques
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2781405A1 (fr) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Peptides lineaires specifiques du recepteur de la melanocortine-1
WO2011063366A1 (fr) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Peptides cycliques spécifiques du récepteur de la mélanocortine-1
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
WO2012021876A2 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
WO2012040459A2 (fr) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Peptides de ciblage de la béta-caténine et leurs utilisations
CA2825098C (fr) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine et derives de pyrazolopyrimidine en tant que modulateurs du recepteur de la melanocortine-4
WO2012174423A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Polypeptides stabilisés comme régulateurs de fonction gtpase rab
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
SG10201913593WA (en) 2013-03-13 2020-02-27 Harvard College Stapled and stitched polypeptides and uses thereof
CA2915354A1 (fr) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Modulateurs stabilises du recepteur de l'insuline polypeptidique
WO2015179635A2 (fr) 2014-05-21 2015-11-26 President And Fellows Of Harvard College Peptides inhibiteurs de ras et leurs utilisations
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
WO2016049359A1 (fr) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
DE69212011T2 (de) 1991-02-15 1997-01-09 Takeda Chemical Industries Ltd Endothelin Antagoniste
ATE155486T1 (de) 1991-08-13 1997-08-15 Takeda Chemical Industries Ltd Zyklische peptide und ihre verwendung
ES2133295T3 (es) 1991-11-19 1999-09-16 Takeda Chemical Industries Ltd Peptidos ciclicos y su uso.
EP0547317A1 (fr) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Antagonistes d'endothéline
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
JP3553062B2 (ja) 1992-07-27 2004-08-11 ジ アドミニストレイターズ オブ ザ トュラン エデュケーショナル ファンド ニューロメジンｂ受容体拮抗物質
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (fr) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Composition pour la prévention et le traitement de maladies de la circulation pulmonaire
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
WO1996034012A1 (fr) 1995-04-28 1996-10-31 Takeda Chemical Industries, Ltd. Antagonistes des recepteurs lh-rh pentapeptidiques cycliques
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JP3784418B2 (ja) 1996-06-11 2006-06-14 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体およびラパマイシンの配合
JP3947228B2 (ja) 1996-06-25 2007-07-18 株式会社日清製粉グループ本社 環状デプシペプチドおよびこれを有効成分とする医薬
EP0815870A3 (fr) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition de prophylaxie et de traitement d'infarction cérébrale
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
EP0946595A2 (fr) 1996-12-17 1999-10-06 Quadrant Holdings Cambridge Limited Melanocortines
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
WO2000058361A1 (fr) 2000-10-05
NO20014568D0 (no) 2001-09-20
SK13082001A3 (sk) 2002-03-05
PL350095A1 (en) 2002-11-04
ID30262A (id) 2001-11-15
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
HUP0202203A3 (en) 2003-09-29
RU2213098C2 (ru) 2003-09-27
AR023201A1 (es) 2002-09-04
HK1044954B (zh) 2008-11-21
JP2002542159A (ja) 2002-12-10
MA25403A1 (fr) 2002-04-01
CN1249086C (zh) 2006-04-05
SA00210192B1 (ar) 2006-06-04
KR20050009722A (ko) 2005-01-25
CA2368431A1 (fr) 2000-10-05
CZ20013407A3 (cs) 2002-02-13
HUP0202203A2 (en) 2002-10-28
NZ514141A (en) 2004-01-30
DE60038734T2 (de) 2009-07-02
CA2368431C (fr) 2006-01-24
HK1044954A1 (en) 2002-11-08
DE60038734D1 (de) 2008-06-12
ZA200107411B (en) 2002-05-29
US20040023859A1 (en) 2004-02-05
AU4017900A (en) 2000-10-16
KR100519201B1 (ko) 2005-10-06
MXPA01009881A (es) 2002-05-06
AU763510B2 (en) 2003-07-24
TR200102765T2 (tr) 2002-05-21
EP1165613A1 (fr) 2002-01-02
PE20001641A1 (es) 2001-02-07
EP1165613B1 (fr) 2008-04-30
ES2304345T3 (es) 2008-10-16
US6613874B1 (en) 2003-09-02
KR100558131B1 (ko) 2006-03-10
PT1165613E (pt) 2008-07-29
CO5170531A1 (es) 2002-06-27
CN1345335A (zh) 2002-04-17
NO20014568L (no) 2001-11-29
MY126585A (en) 2006-10-31
ATE393783T1 (de) 2008-05-15
KR20020008143A (ko) 2002-01-29
BR0009497A (pt) 2002-01-15
IL145406A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
DE60038734D1 (de) Melanocortinrezeptor-liganden
NO2022060I1 (no) Aflibercept
NO20026280L (no) Melanokortin reseptor-ligander
AU9631301A (en) Melanocortin receptor ligands
ID26447A (id) Turunan eritropoietin
DE60044873D1 (de) Orientierte biopolymermembrane
DE60039942D1 (de) Selbstbräununsschaum
DE50007721D1 (de) Trageinrichtung
NO20013954L (no) Understöttelsesanordning
NO20013997L (no) Reseptoranalyse
DE59911248D1 (de) Halterung
ID30214A (id) Turunan resorsinol
DE50015643D1 (de) Dekorelement
NO20014961D0 (no) Integrin-reseptor-ligander
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
DE50000236D1 (de) Halterungsanordnung
DE50007184D1 (de) Halterungsanordnung
ATA121799A (de) Ausbeulgerät
DE60020365D1 (de) Säurekatalysierte umsetzungen
ATA107599A (de) Heizwasserbereiter
ATA732000A (de) Kachelofen
AT500658A3 (de) Isolierplatte
NO994224L (no) Underlagsmatte
FI4253U1 (fi) Taka-ajovalorakenne
ES1045226Y (es) Soporte antivibrante mejorado